Key Takeaways on the Clinical Utility of ctDNA in Colorectal Cancer

Among patients with rectal cancer who underwent total mesorectal excision following SCRT plus camrelizumab and chemotherapy, the 3-year OS rate was 93.3%.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

At the time of analysis, the median progression-free survival was not reached with fruquintinib plus capecitabine in a phase 1/2 trial.

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

Results from the phase 3 CodeBreaK trial support the use of 960 mg of sotorasib plus panitumumab as standard of care in metastatic colorectal cancer.

Treatment-related adverse events of special interest occurred in 64.9% of patients who received fruquintinib and 23.0% of those who received placebo.